fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-06-07
Company: Molmed (Italy)
Investors: Regione Lombardia (Italy)
Amount: € 1.4 million
Planned use: This grant has been awarded for an R&D project aimed at developing an automated manufacturing process for MoldMed's cell-based therapy TK.
It will partially cover R&D expenses of the project over a 36 month period. MolMed's partners in this project are Areta International and Datamed. They will develop an automated closed system for the manufacturing of TK which consists of patient-specific genetically engineered cells.
Other: MolMed's cell-based therapy TK is currently in phase III for high-risk leukaemias (seeclinical_studies).